HER2-positive BC is often treated with targeted therapies, including trastuzumab (Herceptin) and lapatinib (Tykerb), a dual tyrosine kinase inhibitor of HER2 and EGFR (Dean, 2012). This evidence concerns the gene EGFR and breast cancer.